Mary-Rabine L, Kulbertus H E
University of Liège, Belgium.
Cardiology. 1990;77(6):443-9. doi: 10.1159/000174636.
Seventy-seven patients with symptomatic atrial fibrillation (AF) received oral flecainide acetate (247 +/- 8 mg/day). In 66 patients, previous antiarrhythmic trials consisted of 1-9 drugs. In 55 cases, AF was paroxysmal. It was persistent in 22 patients. Conversion and/or no recurrence of AF was achieved in 40 patients (52%) by flecainide alone and in 11 (14%) by the combination of flecainide and amiodarone. The mean flecainide serum level was 535 +/- 46 ng/ml. Age, presence of coronary artery disease or electrocardiographic parameters were not useful for predicting clinical response. In persistent AF, flecainide efficacy decreased with the duration of arrhythmia. Side effects concerned conduction (26%) and congestive heart failure (5%).
77例有症状的心房颤动（AF）患者口服醋酸氟卡尼（247±8mg/天）。66例患者之前的抗心律失常试验使用过1 - 9种药物。55例为阵发性房颤，22例为持续性房颤。单用氟卡尼使40例患者（52%）房颤转复和/或未复发，氟卡尼与胺碘酮联合使用使11例患者（14%）房颤转复和/或未复发。氟卡尼血清平均水平为535±46ng/ml。年龄、冠状动脉疾病的存在或心电图参数对预测临床反应均无帮助。在持续性房颤中，氟卡尼的疗效随心律失常持续时间延长而降低。副作用涉及传导系统（26%）和充血性心力衰竭（5%）。
